Tin tức & Cập nhật

Upfront osimertinib matches sequential treatment for prolonging survival in EGFR-mutant NSCLC
Upfront osimertinib matches sequential treatment for prolonging survival in EGFR-mutant NSCLC
10 Jun 2023 bởiJairia Dela Cruz

Patients with nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation appear to experience similar survival outcomes with either frontline osimertinib therapy or sequential treatment approach of gefitinib followed by osimertinib, although upfront osimertinib leads to a significant reduction in the risk of brain progression, as shown in the results of the APPLE trial presented at ELCC 2023.

Upfront osimertinib matches sequential treatment for prolonging survival in EGFR-mutant NSCLC
10 Jun 2023
Omega-3 fatty acids lower risk of dementia, cognitive decline
Omega-3 fatty acids lower risk of dementia, cognitive decline
10 Jun 2023
NAFLD a risk factor for young-onset hypertension
NAFLD a risk factor for young-onset hypertension
09 Jun 2023

Young people with nonalcoholic fatty liver disease (NAFLD) are at increased risk of hypertension, especially women and those with more severe hepatic steatosis, as shown in a study.

NAFLD a risk factor for young-onset hypertension
09 Jun 2023
Nonchemotherapy doublet shows therapeutic potential in PD-1/PD-L1 inhibitor‒resistant NSCLC
Nonchemotherapy doublet shows therapeutic potential in PD-1/PD-L1 inhibitor‒resistant NSCLC
09 Jun 2023
New HF criteria set sizeable shift of individuals from stage A to B
New HF criteria set sizeable shift of individuals from stage A to B
09 Jun 2023

The new standards for heart failure (HF) staging proposed in the 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) clinical practice guideline has led to a considerable change among community-based individuals from stage A to B.

New HF criteria set sizeable shift of individuals from stage A to B
09 Jun 2023